Clinical Research Directory

Inclusion Criteria: * Provide written informed consent * Fulfill ACR/EULAR 2023 CPPD classification criteria * Acute or chronic joint inflammation currently or in the past 3 months, not attributable to another condition (Joint Inflammation defined as: At least 1 joint this is swollen, red, or warm to the touch; with or without corresponding tenderness) * Pain visual analog scale (pain VAS) \>=30 at screening Exclusion Criteria: * Age \<40 years * Chronic diarrhea * Gout, rheumatoid arthritis, psoriatic arthritis, or cirrhosis * Ongoing use of colchicine and unwilling to undergo a 30-day wash-out period (note: patients using colchicine at screening can enroll if they agree to a 30-day wash-out before randomization) * Pregnant or breast-feeding * Use of methotrexate, hydroxychloroquine, tocilizumab or canakinumab in the past 4 weeks * Use of anakinra, oral glucocorticoid, or intra-articular steroid in the past 1 week * Ongoing use of strong CYP3A4 inhibitors per FDA package insert for colchicine * Ongoing use of P-glycoprotein inhibitors per FDA package insert for colchicine * Known allergy to colchicine * Planned joint surgery in the next 6 months * CPPD clinical presentation isolated to Crowned Dens Syndrome with no additional peripheral joint involvement * Screening labs with any of the following: 1. Hemoglobin \< 9 g/dL 2. WBC \<3 x 10\^9/L 3. Platelets \<110 x10\^9/L 4. Creatinine clearance (CrCl) \<30 mL/min 5. ALT or AST \>3x upper limit of normal (ULN) * Patient is considered by investigator to be an unsuitable candidate for the study for any reason